Cytokinetics Inc

CYTK's Stage 2 uptrend has entered a terminal Blow-Off Top phase marked by extreme overbought readings and high Stage 213 transition risk. The active Blow-Off Top pattern and rejection at recent highs indicate unsustainable buying pressure and initial pullback, warranting a Sell Now into the spike high/resistance zone.

• ↑Q1 myCORSO net product revenue reached $4.8M in nine weeks
• ↑Total revenues jumped to $19.4M from $1.6M YoY on launch momentum
• ↓Q1 net loss totaled $206M, raising burn‐rate concerns